Literature DB >> 9570292

Escape from host-antitumor immunity.

G Pawelec1, J Zeuthen, R Kiessling.   

Abstract

Cancer cells may express proteins recognizable by the individual's immune system as foreign because they are either tumor-specific or not expressed at high levels in normal tissues to which the host is tolerant. There is now much evidence that tumors can be immunogenic, that is, that they frequently express antigens in a form recognizable by the host immune system. This has been shown not only in experimental animals but also for spontaneously occurring human tumors. Tumors therefore may progress by evolving variants that can evade immune responses or by developing other strategies to "escape" the immune response. The purpose of this review is to consider the current status of knowledge concerning these different tumor escape strategies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9570292     DOI: 10.1615/critrevoncog.v8.i2-3.10

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  10 in total

Review 1.  T cell receptor usage in malignant diseases.

Authors:  E Halapi; M Jeddi-Tehrani; A Osterborg; H Mellstedt
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  VEGF as a mediator of tumor-associated immunodeficiency.

Authors:  J E Ohm; D P Carbone
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

3.  Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model.

Authors:  Charles H Lineweaver; Paul C W Davies; Mark D Vincent
Journal:  Bioessays       Date:  2014-07-14       Impact factor: 4.345

Review 4.  Specific immunotherapy of cancer in elderly patients.

Authors:  S Matzku; M Zöller
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

5.  Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice.

Authors:  Assefa Wondimu; Tianqian Zhang; Thomas Kieber-Emmons; Phyllis Gimotty; Katrin Sproesser; Rajasekharan Somasundaram; Soldano Ferrone; Chun-Yen Tsao; Dorothee Herlyn
Journal:  Cancer Immunol Immunother       Date:  2008-07       Impact factor: 6.968

6.  Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells.

Authors:  A D Gritzapis; A Mamalaki; A Kretsovali; J Papamatheakis; M Belimezi; S A Perez; C N Baxevanis; M Papamichail
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

Review 7.  Oligoclonal T cells in human cancer.

Authors:  E Halapi
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

8.  Use of recombinant lentivirus pseudotyped with vesicular stomatitis virus glycoprotein G for efficient generation of human anti-cancer chimeric T cells by transduction of human peripheral blood lymphocytes in vitro.

Authors:  Anthony Simmons; Robert P Whitehead; Andrey A Kolokoltsov; Robert A Davey
Journal:  Virol J       Date:  2006-02-28       Impact factor: 4.099

9.  In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas.

Authors:  D Bell; P Chomarat; D Broyles; G Netto; G M Harb; S Lebecque; J Valladeau; J Davoust; K A Palucka; J Banchereau
Journal:  J Exp Med       Date:  1999-11-15       Impact factor: 14.307

10.  The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase.

Authors:  Rikke Baek Sørensen; Linda Berge-Hansen; Niels Junker; Christina Aaen Hansen; Sine Reker Hadrup; Ton N M Schumacher; Inge Marie Svane; Jürgen C Becker; Per thor Straten; Mads Hald Andersen
Journal:  PLoS One       Date:  2009-09-07       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.